About Salmedix
Salmedix is a Healthcare company based in San Diego (United States) founded in 2000, and was acquired by Cephalon in May 2005. Drugs for hematologic cancers are developed using prior clinical data. Salmedix has raised $72.5 million across 3 funding rounds from investors including ARE, Orbimed and Cephalon. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer. Its competitors include Adicet Bio, Orca Bio and Ossium Health; 3 of its 3 listed competitors have raised funding.
Company details
Salmedix was founded in 2000 and is based in San Diego, United States. Operations are conducted in the biotechnology sector, where compounds for treating hematologic cancers are developed. Prior human clinical data is leveraged in these compounds to enable a shorter and less costly development timeline. The lead pipeline product, SDX-105, is targeted at non-Hodgkins lymphoma.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website salmedix.com
- Social LinkedIn
- Acquired by Cephalon (May 2005)
Funding Insights of Salmedix
Salmedix has successfully raised a total of $72.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $45 million completed in October 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.5M
- Total Rounds 3
- Last Round Series C — $45M
- First Round $27.5M
(Jun 2002)
- Investors Count 18
All 3 funding rounds of Salmedix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2005 | $45M | Series C | – | – | |
| Jun 2004 | Series C | – | – | ||
| Jun 2002 | $27.5M | Series B | – | Garywoitzik, Delphi Ventures |
19 investors in total: 19 institutional.
Investors in Salmedix
Salmedix has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Orbimed and Cephalon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
| eastoncapital.com | ||||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
| cmea.com | ||||
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
| proquestvc.com | ||||
Early-stage investments in Canadian companies are made by Ventures West. | ventureswest.com | Vancouver, Canada | ||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
| genechem.com |
Investor details for Salmedix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Salmedix
4 dated milestones of Salmedix across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Salmedix is founded.
- Funding First funding round of $27.5M.
- Exit Acquired by Cephalon.
- Funding Latest funding round, Series C, of $45.0M.
Competitors of Salmedix
Salmedix has 3 listed competitors in our database, 3 of them funded. They include Adicet Bio, Orca Bio and Ossium Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adicetbio.com | 2014 | Menlo Park, United States | $51M | 86 | Immune cell therapies for cancer treatment are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $300M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| ossiumhealth.com | 2016 | San Francisco, United States | $125.41M | Ossium Health is focused on bioengineering for improved health. |
Detailed competitors of Salmedix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Salmedix (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Salmedix
Salmedix was founded in 2000 and raised its 1st funding round 2 years after it was founded.
Salmedix is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Salmedix is a funded company, having raised a total of $72.5M across 3 funding rounds to date. The company's 1st funding round was a Series B of $27.5M, raised on Jun 2002.
Salmedix was founded in 2000 and is based in San Diego, United States. Operations are conducted in the biotechnology sector, where compounds for treating hematologic cancers are developed. Prior human clinical data is leveraged in these compounds to enable a shorter and less costly development timeline. The lead pipeline product, SDX-105, is targeted at non-Hodgkins lymphoma.
Salmedix's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Salmedix has 19 investors. Key investors include ARE, Orbimed, Cephalon, Bemberg Capital, and H.I.G. Capital.
Yes. Salmedix was acquired by Cephalon in May 2005.